Loading quotes...

Forecast

The analysts' average price target is €81.57 (+331.59%). The median is €81.57 (+331.59%).

Buy	14
Hold	0
Sell	0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

Structure Therapeutics advances development of oral obesity drugs

Structure Therapeutics reported progress at the Cantor Fitzgerald Healthcare Conference on its oral GLP-1 program Aleniglipron and the oral amylin candidate ACCG-2671. Aleniglipron is in two initiated global Phase III trials (ACCOMPLISH-1/2) with data targeted for the end of 2028, and the company reports $1.3 billion in cash to fund key milestones. Initial human data for ACCG-2671 showed a half-life of six days, no adverse events at low doses, and an early weight loss of 3.3% in the 10 mg cohort; 12-week data are expected in the first half of next year. Management highlighted the market opportunity for oral GLP-1 agents, which already account for 17% of the market, and expressed openness to strategic partnerships and combination approaches. » More on de.investing.com

Financials

In the last quarter, STRUCTURE THERAPEUTICS INC ADR had revenue of €0 and net profit of -€127.8m

(EUR)	September 2026	YoY
Revenue	0	-
Gross profit	0	-
Net profit	-127.8m	128.23%
EBITDA	-127.59m	129.49%

Fundamentals

Metric	Value
Market capitalization	€1.09bn
Number of shares	57.57m
52-week high/low	€85.54 - €16.86
Dividends	No
Beta	-1.52
P/E ratio	-5.37
PEG ratio	0.20
P/B ratio	1.25
P/S ratio	0.00

Company profile

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.

Name	STRUCTURE THERAPEUTICS INC ADR
CEO	Raymond C. Stevens
Headquarters	South San Francisco, ca USA
Website	structuretx.com
Industry	Chemicals
IPO	03/02/2023
Employees	281